Vaspin – a link of obesity and psoriasis?

Abstract:  Psoriasis is an inflammatory skin disease often associated with obesity. The anti‐inflammatory adipokine vaspin, a suggested serine proteinase inhibitor of the serpin family, is discussed as a new link between inflammation and obesity. Here, we demonstrate that – different from healthy controls – vaspin serum levels in patients with psoriasis were body mass index independent. Moreover, we could identify keratinocytes as the major source of vaspin in skin. Vaspin expression in lesional psoriatic skin was reduced compared with uninvolved skin as shown by immunohistochemistry and RT‐PCR. In aggregate, we report on the cellular source of vaspin in skin and its expression in psoriasis.

[1]  M. Okada,et al.  Vaspin prevents TNF-α-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF-κB and PKCθ activation in cultured rat vascular smooth muscle cells. , 2011, Pharmacological research.

[2]  M. Fasshauer,et al.  Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects , 2011, Diabetologia.

[3]  W. Boehncke,et al.  The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity , 2011, Experimental dermatology.

[4]  D. Gladman,et al.  Cardiovascular Comorbidities in Psoriasis and Psoriatic Arthritis: Pathogenesis, Consequences for Patient Management, and Future Research Agenda: A Report from the GRAPPA 2009 Annual Meeting , 2011, The Journal of Rheumatology.

[5]  A. Gottlieb,et al.  Comorbidities in patients with psoriasis. , 2009, The American journal of medicine.

[6]  F. Cordido,et al.  Vaspin and amylin are expressed in human and rat placenta and regulated by nutritional status. , 2009, Histology and histopathology.

[7]  T. Kanda,et al.  A Novel Adipocytokine, Visceral Adipose Tissue-derived Serine Protease Inhibitor (Vaspin), and Obesity , 2008, The Journal of international medical research.

[8]  M. Fasshauer,et al.  Serum Vaspin Concentrations in Human Obesity and Type 2 Diabetes , 2008, Diabetes.

[9]  J. Gómez-Reino,et al.  Adipokines as emerging mediators of immune response and inflammation , 2007, Nature Clinical Practice Rheumatology.

[10]  P. Wincker,et al.  Large-scale identification of human genes implicated in epidermal barrier function , 2007, Genome Biology.

[11]  D. Zahger,et al.  Psoriasis and the metabolic syndrome. , 2007, Acta dermato-venereologica.

[12]  M. Weichenthal,et al.  Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis , 2006, Archives of Dermatological Research.

[13]  M. Fasshauer,et al.  Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. , 2006, Biochemical and biophysical research communications.

[14]  Eijiro Watanabe,et al.  Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.